Sutro Works Toward A Better Ovarian Cancer ADC

Sutro Biopharma, Inc. chose to focus its cell-free protein synthesis technology platform on antibody-drug conjugates (ADCs) long before ADCs were elevated to high-value status in recent years, and the company has used business development strategically to raise funding for its wholly owned development programs and to advance its XpressCF platform. Now, its lead ADC candidate luveltamab tazevibulin (luvelta) is in a pivotal trial to see if Sutro can deliver a better ovarian cancer option.